SMARCA2 and neoplasm: PFI‐3 was originally developed as a highly selective small molecule BRD inhibitor of the BRG1 and BRM subunits of the SWI/SNF complex, which has minimal “off‐target” effects in primary human cells and no evidence of toxicity on the NCI‐60 panel of tumour cell lines [18, 19].